Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice

Journal of Investigative Dermatology

Volumn 113, Issue 1, 1999, Pages 22-25

  Mahoney, My G ^a,b   Wang, Zhi Hong ^a   Stanley, John R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cell adhesion; Desmoglein; Desmosome; Protease

Indexed keywords

IMMUNOGLOBULIN G; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACANTHOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLISTER; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; MOUSE; NEWBORN; NONHUMAN; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032809239     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00632.x     Document Type: Article

References (22)

1. Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869-877, 1991
2. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306:1189-1196, 1982
3. Anhalt GJ, Patel HP, Labib RS, Diaz LA, Proud D: Dexamethasone inhibits plasminogen activator activity in experimental pemphigus in vivo but does not block acantholysis. J Immunol 136:113-117, 1986
4. Baird J: mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. J Invest Dermatol 95:548-552, 1990
5. Buxton RS, Cowin P, Franke WW, et al: Nomenclature of the desmosomal cadherins. J Cell Biol 121:481-483, 1993
6. Carmeliet P, Schoonjans L, Kieckens L, et al: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424, 1994
7. Esaki C, Seishima M, Yamada T, Osada K, Kitajima Y: Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line. J Invest Dermatol 105:329-333, 1995
8. Farb RM, Dykes R, Lazarus GS: Anti-epidermal-cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of proteinase. Proc Natl Acad Sci USA 75:459-463, 1978
9. Hashimoto K, Shafran KM, Webber PS, Lazarus GS, Singer KH: Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. J Exp Med 157:259-272, 1983
10. Hashimoto K, Wun TC, Baird J, Lazarus GS, Jensen PJ: Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. J Invest Dermatol 92:310-314, 1989
11. Jensen PJ: Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 90:777-782, 1988
12. Koch PJ, Mahoney MG, Ishikawa H, et al: Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 137:1091-1102, 1997
13. Koulu L, Kusumi A, Steinberg MS, Klaus Kovtun V, Stanley JR: Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. J Exp Med 160:1509-1518, 1984
14. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR: Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 103:461-468, 1999
15. Morioka S, Lazarus GS, Jensen PJ: Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. J Invest Dermatol 89:474-477, 1987
16. Naito K, Morioka S, Nakajima S, Ogawa H: Proteinase inhibitors block formation of pemphigus acantholysis in experimental models of neonatal mice and skin explants: effects of synthetic and plasma proteinase inhibitors on pemphigus acantholysis. J Invest Dermatol 93:173-177, 1989
17. Schiltz JR, Michel B, Papay R: Appearance of "pemphigus acantholysis factor" in human skin cultured with pemphigus antibody. J Invest Dermatol 73:575-581, 1979
18. Spiers EM, Lazarus GS, Lyons Giordano B: Expression of plasminogen activator enzymes in psoriatic epidermis. J Invest Dermatol 102:333-338, 1994
19. Spiers EM, Lazarus GS, Lyons-Giordano B: Expression of plasminogen activators in basal cell carcinoma. J Pathol 178:290-296, 1996
20. Stanley JR: Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest 83:1443-1448, 1989
21. Stanley JR: Pemphigus: skin failure mediated by autoantibodies. JAMA 264:1714-1717, 1990
22. Stanley JR: Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 53:291-325, 1993